Cargando…

Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution

Although extranodal NK/T cell lymphoma (ENKTCL) is consistently associated with Epstein-Barr virus (EBV) infection, the manifestation and prognostic value of serum EBV antibodies still remain unknown. One hundred and forty-one patients with ENKTCL were evaluated for serum EBV EA-IgA and VCA-IgA anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yuhua, Rao, Huilan, Yan, Shumei, Wang, Fang, Wu, Qinian, Feng, Yanfen, Zhang, Yujing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486802/
https://www.ncbi.nlm.nih.gov/pubmed/28550598
http://dx.doi.org/10.1007/s00277-017-3013-y
_version_ 1783246334115971072
author Huang, Yuhua
Rao, Huilan
Yan, Shumei
Wang, Fang
Wu, Qinian
Feng, Yanfen
Zhang, Yujing
author_facet Huang, Yuhua
Rao, Huilan
Yan, Shumei
Wang, Fang
Wu, Qinian
Feng, Yanfen
Zhang, Yujing
author_sort Huang, Yuhua
collection PubMed
description Although extranodal NK/T cell lymphoma (ENKTCL) is consistently associated with Epstein-Barr virus (EBV) infection, the manifestation and prognostic value of serum EBV antibodies still remain unknown. One hundred and forty-one patients with ENKTCL were evaluated for serum EBV EA-IgA and VCA-IgA antibodies levels in the past 24 years in our institution. Their correlation with clinicopathological features, plasma EBV DNA load, and patients’ outcomes was analyzed. EBV EA-IgA ≥1:10 and VCA-IgA ≥1:160 were found in 18.4 and 16.3% of patients, respectively. They correlated with adverse ENKTCL profile and inferior overall survival (OS) and progression-free survival (PFS). EA-IgA ≥1:10 was an independent prognostic factor on OS (RR = 2.276, p = 0.008) and associated with lower complete response (CR) rate (34.8 vs 70.6%, p = 0.001) and higher relapse rate in CR patients (62.5 vs 34.7%, p = 0.016). In subgroup analysis, both EA-IgA ≥1:10 and VCA-IgA ≥1:160 significantly correlated with inferior OS and PFS in patients with stage I/II, IPI score 0–1, plasma EBV DNA (+), and CR. Patients with plasma EBV DNA (+) and EA-IgA ≥1:10 (or VCA-IgA ≥1:160) had significantly shorter periods of OS and PFS in comparison with other corresponding groups. Elevated serum EBV EA-IgA and VCA-IgA levels were related to adverse ENKTCL profile and correlated with poor treatment response, early relapse, and poor prognosis in patients with ENKTCL. These findings provide convincing evidence for the use of serum EBV EA-IgA and VCA-IgA antibodies for risk group stratification and prognostic prediction in ENKTCL. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00277-017-3013-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5486802
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-54868022017-07-11 Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution Huang, Yuhua Rao, Huilan Yan, Shumei Wang, Fang Wu, Qinian Feng, Yanfen Zhang, Yujing Ann Hematol Original Article Although extranodal NK/T cell lymphoma (ENKTCL) is consistently associated with Epstein-Barr virus (EBV) infection, the manifestation and prognostic value of serum EBV antibodies still remain unknown. One hundred and forty-one patients with ENKTCL were evaluated for serum EBV EA-IgA and VCA-IgA antibodies levels in the past 24 years in our institution. Their correlation with clinicopathological features, plasma EBV DNA load, and patients’ outcomes was analyzed. EBV EA-IgA ≥1:10 and VCA-IgA ≥1:160 were found in 18.4 and 16.3% of patients, respectively. They correlated with adverse ENKTCL profile and inferior overall survival (OS) and progression-free survival (PFS). EA-IgA ≥1:10 was an independent prognostic factor on OS (RR = 2.276, p = 0.008) and associated with lower complete response (CR) rate (34.8 vs 70.6%, p = 0.001) and higher relapse rate in CR patients (62.5 vs 34.7%, p = 0.016). In subgroup analysis, both EA-IgA ≥1:10 and VCA-IgA ≥1:160 significantly correlated with inferior OS and PFS in patients with stage I/II, IPI score 0–1, plasma EBV DNA (+), and CR. Patients with plasma EBV DNA (+) and EA-IgA ≥1:10 (or VCA-IgA ≥1:160) had significantly shorter periods of OS and PFS in comparison with other corresponding groups. Elevated serum EBV EA-IgA and VCA-IgA levels were related to adverse ENKTCL profile and correlated with poor treatment response, early relapse, and poor prognosis in patients with ENKTCL. These findings provide convincing evidence for the use of serum EBV EA-IgA and VCA-IgA antibodies for risk group stratification and prognostic prediction in ENKTCL. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00277-017-3013-y) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2017-05-27 2017 /pmc/articles/PMC5486802/ /pubmed/28550598 http://dx.doi.org/10.1007/s00277-017-3013-y Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Huang, Yuhua
Rao, Huilan
Yan, Shumei
Wang, Fang
Wu, Qinian
Feng, Yanfen
Zhang, Yujing
Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution
title Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution
title_full Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution
title_fullStr Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution
title_full_unstemmed Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution
title_short Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution
title_sort serum ebv ea-iga and vca-iga antibodies can be used for risk group stratification and prognostic prediction in extranodal nk/t cell lymphoma: 24-year experience at a single institution
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486802/
https://www.ncbi.nlm.nih.gov/pubmed/28550598
http://dx.doi.org/10.1007/s00277-017-3013-y
work_keys_str_mv AT huangyuhua serumebveaigaandvcaigaantibodiescanbeusedforriskgroupstratificationandprognosticpredictioninextranodalnktcelllymphoma24yearexperienceatasingleinstitution
AT raohuilan serumebveaigaandvcaigaantibodiescanbeusedforriskgroupstratificationandprognosticpredictioninextranodalnktcelllymphoma24yearexperienceatasingleinstitution
AT yanshumei serumebveaigaandvcaigaantibodiescanbeusedforriskgroupstratificationandprognosticpredictioninextranodalnktcelllymphoma24yearexperienceatasingleinstitution
AT wangfang serumebveaigaandvcaigaantibodiescanbeusedforriskgroupstratificationandprognosticpredictioninextranodalnktcelllymphoma24yearexperienceatasingleinstitution
AT wuqinian serumebveaigaandvcaigaantibodiescanbeusedforriskgroupstratificationandprognosticpredictioninextranodalnktcelllymphoma24yearexperienceatasingleinstitution
AT fengyanfen serumebveaigaandvcaigaantibodiescanbeusedforriskgroupstratificationandprognosticpredictioninextranodalnktcelllymphoma24yearexperienceatasingleinstitution
AT zhangyujing serumebveaigaandvcaigaantibodiescanbeusedforriskgroupstratificationandprognosticpredictioninextranodalnktcelllymphoma24yearexperienceatasingleinstitution